Articles tagged with Medulloblastoma
A team of St. Jude researchers discovered a medulloblastoma subtype that can be treated with reduced-intensity chemotherapy, improving survival rates for infants. The study found that 75% of patients with the subtype were alive five years after diagnosis, with low-risk patients having even better outcomes.
Researchers have identified six genes associated with an increased risk of developing medulloblastoma, a common childhood brain tumor. Genetic screening guidelines have been developed to help patients understand their lifetime cancer risk and manage their care.
Research findings show that PD-L1 expression facilitates immune escape in medulloblastoma patients. The study identifies subgroup-specific variations in PD-L1 expression and its relationship with therapeutic responses. Immune adjuvant therapies may be necessary to fully realize the benefits of PD-1 blockade treatments.
A recent UTSW study sheds light on the mechanisms underlying Sonic Hedgehog subtype medulloblastoma development, revealing a crucial role for the G protein-coupled receptor Gpr161. The research suggests that Gpr161 acts as a tumor suppressor by preventing excessive granule cell proliferation.
Researchers from CNRS and St. Jude Children's Research Hospital have identified a gene cluster involved in medulloblastoma tumour development. They found that genes normally expressed only in the eye can be activated in brain tumors, promoting cell proliferation and inhibiting cell death.
Researchers at Queen Mary University of London have identified a new weakness in medulloblastoma, the most common form of childhood brain tumour, which could lead to more targeted treatments. The study found that high levels of BMI1 and low levels of CHD7 are associated with poor prognosis in aggressive human medulloblastoma.
Researchers at St. Jude Children's Research Hospital have discovered a promising target for precision medicines to block the Sonic Hedgehog signaling pathway, which drives cell proliferation in medulloblastoma. Inhibiting this pathway using an investigational drug INK128 significantly extended the lives of mice with the tumor.
A comprehensive genomic analysis of over 500 medulloblastoma patients revealed new mutations and genetic missteps, including two suspected oncogenes. The discoveries will aid efforts to develop precision medicines with increased survival rates and reduced side effects.
Childhood medulloblastoma can be separated into seven distinct subgroups with unique biological and clinical characteristics. This new understanding may lead to increased survival rates as each subgroup responds differently to treatment, allowing for tailored treatment options. The study aims to improve diagnosis and treatment outcomes...
A study by St. Jude Children's Research Hospital scientists shows that the histone writer enzyme Ezh2 can both suppress and drive the most aggressive form of medulloblastoma. Inhibiting this enzyme could be counterproductive for cancer treatment in certain situations.
A team of researchers at Massachusetts General Hospital has identified a mechanism controlling the growth of medulloblastoma, the most common pediatric brain tumor. The study found that OTX2 is a critical factor regulating gene expression programs in Group 3 medulloblastoma, and its suppression can reduce tumor growth and survival.
A research team at the Krembil Research Institute has discovered a genetic signaling pathway that controls blood vessel development in the brain can stop brain tumor formation. Blocking this pathway, Norrin/Frizzled4 (Fzd4), creates more opportunities to form pre-cancerous growths and speed up tumour initiation.
Researchers identify ATR gene as crucial for brain tumor growth and development, developing nanoparticle-formulated drug to block tumor growth. The investigational treatment shows promise in reducing cerebellar growth by causing cell death in neural progenitors.
Researchers at Johns Hopkins Kimmel Cancer Center have developed a system using transformed human stem cells to speed up screening of existing drugs for rare brain and other cancers. This method enables more confident comparison with human cells, leading to promising treatments like CDK inhibitors for Group 3 medulloblastoma.
Paul A. Northcott, a researcher at St. Jude Children's Research Hospital, has been selected as a Pew-Stewart Scholar to tackle medulloblastoma, the most common malignant pediatric brain tumor. The award includes four years of funding and aims to develop much-needed therapies for patients who relapse.
Researchers have identified a new combination therapy for the most aggressive form of medulloblastoma, a fast-growing type of pediatric brain cancer. The study found that combining two drugs, histone deacetylase inhibitors and phosphatidylinositol 3-kinase inhibitors, potently kills cancer cells with minimal toxicity.
A new study suggests that proton beam therapy is as safe and effective as conventional radiotherapy in treating childhood brain cancer, medulloblastoma. The treatment may also reduce the risk of long-term side effects such as hearing loss and endocrine problems.
Researchers have identified the cells responsible for childhood brain tumor subtype Group 4 medulloblastoma, a breakthrough that may lead to more effective treatments. By studying the epigenome, scientists found that these tumors originate from neural stem cells in the developing cerebellum.
Researchers identified a pivotal role of the Miz1 protein in determining tumor identity and its interaction with Myc proteins driving group 3 medulloblastoma. The study suggests targeting the Miz1-Myc complex may suppress the spread of group 3 tumors.
Researchers discovered that blocking a specific ion channel in medulloblastoma can impede tumor cells from proliferating and spreading. The development of targeted treatments could improve outcomes for patients with this disease, which is a common cause of death in children.
A targeted therapy called vismodegib is effective against the SHH subtype of medulloblastoma in adults, which accounts for about 60% of tumors. The drug blocks a key protein in the sonic hedgehog signaling pathway and has been shown to shrink or disappear tumors in four adult participants.
Researchers found DDX3X mutations lead to different molecular defects, requiring tailored therapies. The study identified specific defects for one class of mutants, providing a foundation for individualized treatments.
Researchers at Dana-Farber Cancer Institute have identified Eya1 as a critical protein in both normal brain development and the development of medulloblastoma. Lowering Eya1 levels in mice with medulloblastoma reduced death rates from the disease by half, suggesting it as a prime target for new treatments.
Researchers discovered specific genetic paths that medulloblastoma follows when it relapses, identifying potential subsets of patients treatable with existing drugs. The study suggests taking additional tumor samples at recurrence could lead to more effective treatments.
A new study has identified the SUFU gene mutation as a major contributor to Gorlin syndrome-associated childhood medulloblastoma, significantly increasing the risk of brain tumors in children with this condition. This finding has major implications for treatment and screening protocols for children with Gorlin syndrome.
Researchers at the University of Montreal discovered that Sonic Hedgehog promotes medulloblastoma progression by inducing DNA damage. Inactivation of Boc receptor reduces tumour growth and progression.
Researchers at IRCM discovered that a protein called Sonic Hedgehog induces DNA damage, which promotes the progression of medulloblastoma, the most common brain tumor found in children. The study found that Boc receptor is required for Sonic Hedgehog to induce DNA mutations, reducing tumour growth by 66%.
A novel molecular pathway has been identified that causes aggressive medulloblastoma, and suggests repurposing an anti-depressant medication could help combat the disease. Elevated levels of cAMP may enhance the potency of Sonic hedgehog inhibitors, currently being tested in clinical trials.
Researchers discovered that cancer-causing genes are transcribed in childhood brain tumor cells due to 'hijacked' gene enhancers. The study also found that epigenetic regulation plays a crucial role in the activation of these genes, providing new targets for treatment development.
A collaborative study has identified two oncogenes, GFI1 and GFI1B, that drive the development of medulloblastoma, the most common malignant brain tumor in children. The findings suggest these genes are worthy candidates for molecular-targeted therapy.
Scientists at EMBL and DKFZ identified two sister genes, GFI1B and GFI1, as major drivers of Group 3 medulloblastoma. Large-scale DNA rearrangements relocate these genes, activating them and driving tumour formation.
Researchers identified two adult cancer drugs, pemetrexed and gemcitabine, with potential to improve treatment of high-risk childhood brain tumors. The combination doubled life expectancy of mice with human group 3 medulloblastoma, a subtype with the worst prognosis.
Researchers developed a new method to treat medulloblastoma by disrupting cancer stem cells, halting their ability to proliferate. The approach shows promise in preventing tumor progression and overcoming resistance to therapy, offering hope for patients with this highly malignant cancer.
Researchers identified placental growth factor (PlGF) as crucial for medulloblastoma growth and spread. Blocking this pathway led to regression of all four molecular subtypes in mouse models.
Researchers found that microRNA-218 is low in medulloblastoma patients and its addition stops disease occurrence. The microRNA also affects genes involved in tumor growth and migration, offering potential targets for therapy.
Researchers have analyzed 125 genome analyses of medulloblastomas, identifying frequent and characteristic genomic alterations that may lead to developing new diagnosis and treatment methods. Cells with four sets of chromosomes have been found in several types of cancer, including childhood brain tumors.
Researchers have linked specific gene mutations to four subtypes of medulloblastoma, a malignant brain tumor in children. The discovery could enable personalized treatment and improve patient outcomes.
Researchers at Stanford University School of Medicine have identified several gene mutations responsible for the most common childhood brain tumor, medulloblastoma. The study suggests that these tumors can be categorized into genetically distinct groups with different prognoses and resistance to standard treatments.
Researchers have discovered genes that cooperate in tumor development and identified potential new drug targets for the most aggressive subtype of medulloblastoma. The study found alterations linked to subtypes with the best and worst prognosis, offering new direction for understanding what drives these tumors.
Researchers at Ohio State University Comprehensive Cancer Center develop an oncolytic measles virus to treat disseminated human medulloblastoma. The treatment extended survival by 122% in a model of disseminated brain cancer, with treated animals surviving up to 82 days on average.
Researchers developed a new mouse model to study medulloblastoma, a devastating childhood brain cancer. The model suggests a potential strategy to inhibit tumor growth using PI3-kinase inhibitors, which have shown significant increases in mouse survival.
Researchers have found that treating mice with oculocutaneous albinism caused by mutations in the Tyr gene resulted in improved eye and hair pigmentation when treated with nitisinone. This suggests a potential new treatment for a subset of patients with OCA1B, a form of albinism associated with vision loss.
Researchers identified human cytomegalovirus as a potential target for treating medulloblastoma. The antiviral drug valganciclovir reduced tumor cell growth in both vitro and xenotransplantation in mice.
Researchers have discovered that the regulatory protein FoxM1 is crucial for the growth of malignant childhood brain tumors, medulloblastomas. The level of FoxM1 expressed in tumor cells significantly correlates with patient survival time, making it a useful prognostic marker to guide treatment strategies.
The study found that children with medulloblastoma have fewer genetic alterations than adult counterparts, which may lead to easier therapy development. Genetic changes in pediatric cancers are distinct from adult tumors, and understanding these differences is crucial for improving treatment outcomes.
Researchers identify genetic alterations in medulloblastoma tumors, including mutations in tumor suppressor genes MLL2 and MLL3. This could lead to the development of targeted therapies for children with this type of brain cancer.
Researchers have identified distinct subtypes of medulloblastoma brain tumors originating from unique cells, leading to different treatment approaches. The study's findings support the development of targeted therapies and aid in searching for combinations of cells and mutations that may lead to other cancers.
Researchers have identified six subtypes of childhood brain cancer medulloblastoma with distinct molecular profiles, allowing for more precise and individualized treatment. The study's findings could lead to the development of biomarkers for improved patient outcomes and more effective treatment strategies.
A modified measles virus has been shown to effectively kill medulloblastoma cells in laboratory studies and mouse models, suggesting its potential as a new treatment option for childhood brain tumors. The vaccine strain targets the CD46 receptor, which is highly expressed in multiple tumor types.
Researchers discovered new pyrimidine compounds that target Src tyrosine kinases in medulloblastoma cells, showing reduced cell proliferation and tumor progression. These compounds may offer a more effective treatment option for childhood brain cancer, with potential synergistic effects when combined with chemotherapy.
Researchers found that the master gene Math1 is critical to the development of medulloblastoma, a deadly disease that affects children and young adults. Removing or inactivating Math1 may work as a treatment, but its effectiveness depends on the stage of brain development.
Atoh1, a transcription factor critical for fetal development, is necessary for the development of many forms of medulloblastoma. Shutting down Atoh1 in susceptible brain cells prevented medulloblastoma from developing in mice, suggesting it as a potential target for new drug treatments.
Researchers at UCSF discovered a tiny filament extending from brain cells, known as primary cilia, may play a role in the most common malignant brain tumor in children. The study found that primary cilia are present in some tumors but absent in others, suggesting they may be used by cancer cells to grow.
Researchers discovered medulloblastomas arise from granule cells and only if they are fully committed. They also found protein Olig2 influences cancer cell formation and multiplication. This knowledge could lead to targeted therapies for childhood brain tumors.
Researchers found that proteins BMP2, BMP4 and BMP7 inhibit medulloblastoma tumor growth while inducing malignant cells to develop into normal neurons, offering a potential new treatment for the cancer.
A new approach to radiotherapy and chemotherapy has significantly improved the outcome for children with high-risk medulloblastoma. The study found that this adaptive treatment can cure over 70% of children with this disease.
Researchers at Howard Hughes Medical Institute have created a mouse model of medulloblastoma, a common childhood brain cancer. The study found that mice lacking the XRCC4 gene or both XRCC4 and p53 died early from tumors, which displayed genetic abnormalities characteristic of human medulloblastomas. This new model will help understand...
Researchers at St. Jude Children's Research Hospital develop a strategy to identify 'light bulb genes' linked to medulloblastoma mutations, helping to predict which children will respond to new treatments. The approach could also be applied to other types of cancer.
The study found that the absence or presence of the Ink4c gene can help predict patient outcomes for medulloblastoma. Additionally, the collaboration between Ink4c and Ptch1 genes demonstrates the importance of gene dosage in mediating protective effects against tumorigenesis.
Researchers at Cold Spring Harbor Laboratory have identified a heretofore unknown role for the cyclin-dependent kinase inhibitor INK4C in medulloblastoma development. The study found that Ink4c inactivation cooperates with mutations in Patched to stimulate medulloblastoma formation, even when p53 is intact.